An Australian Patent Opposition, Revocation and Extension of Term Round-Up from the Patent Office Journal dated 25 October 2012.
If you wish to oppose the grant of a patent, or if grant of your own application has been opposed by third parties, please contact us.
Acceptance of the following patent applications has been opposed as at 25 October 2012:
|2005322067 Polymer-von Willebrand factor-conjugates||Baxter Healthcare SA; Baxter International Inc.||William J Pickering.|
|2006240038 Materials and methods for respiratory disease control in canines||Cornell Research Foundation, Inc.; University of Florida Research Foundation, Inc.; The Government of the United States of America As Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention||William J Pickering.|
|2009278275 Method for producing microlenses||Giesecke & Devrient GmbH||Securency International Pty Ltd|
|2010214641 Compositions and methods for the systemic treatment of arthritis||Baylor Research Institute||Shelford Services Pty Limited|
Opposition to acceptance of the following applications has been withdrawn, and the application shall proceed to sealing:
|2004266076 Pharmaceutical product for injection||Nycomed GmbH||Sandoz Pty Ltd|
|2007203451 Pharmaceutical composition containing a crystalline form of perindopril tert-butylamine salt||Les Laboratoires Servier||Apotex Pty Ltd|
|2009295253 A surgical orientation system and associated method||Inertial Orthopaedic Navigation Solutions Pty Ltd||KCAT Investments Pty Limited|
|2010341423 Method and system for managing customer relationships||BNC Ventures B.V.||Susan Matthews.|
No opposition proceedings have been dismissed.
No applications have been withdrawn following opposition.
Extensions of Term of Standard Patents
No applications for Extension of Term under Section 70 have been made.
The following application for Extension of Term has been accepted under Section 75:
|Patent No.||Patentee(s)||Goods & First Reg. Approval|
|2007240156 Peptidomimetic protease inhibitors||Vertex Pharmaceuticals Incorporated||INCIVO telaprevir, 6 March 2012|
The following application(s) for Extension of Term have been granted under Section 76:
|Patent No.||Patentee(s)||Goods & First Reg. Approval||Extension of Term expiry, pursuant to Section 77|
|2001263466 Soluble CTLA4 mutant molecules and uses thereof||Bristol-Myers Squibb Company||NULOJIX belatacept (rch), 15 Mar 2012||23 May 2026|
|2002305758 Pharmaceutical compositions for the coordinates delivery of NSAIDs||Pozen Inc||VIMOVO naproxen and esomeprazole, 25 Oct 2011||25 Oct 2026|
|2010200249 Combines vaccines comprising hepatitis B surface antigen and other antigens||SmithKline Beecham Biologicals (s.a.)||INFANRIX PENTA infanrix penta, 07 Nov 2001||15 May 2013|
Surrendered and Revoked Letters Patent
Surrendered Letters Patent
No patents have been offered for surrender.
Revocation of Letters Patent
No other patents have been wholly or partially revoked.